APA (7th ed.) Citation

GJ, R., ML, L., SE, R., SR, S., GJ, S., Q, A., . . . TL, L. (2020). Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leukemia & lymphoma, 61(5), 1188. https://doi.org/10.1080/10428194.2020.1725503

Chicago Style (17th ed.) Citation

GJ, Roboz, Larson ML, Rubenstein SE, Solomon SR, Schiller GJ, An Q, Chiarella M, Louie AC, and Lin TL. "Final Safety and Efficacy Results from the CPX-351 Early Access Program for Older Patients with High-risk or Secondary Acute Myeloid Leukemia." Leukemia & Lymphoma 61, no. 5 (2020): 1188. https://doi.org/10.1080/10428194.2020.1725503.

MLA (9th ed.) Citation

GJ, Roboz, et al. "Final Safety and Efficacy Results from the CPX-351 Early Access Program for Older Patients with High-risk or Secondary Acute Myeloid Leukemia." Leukemia & Lymphoma, vol. 61, no. 5, 2020, p. 1188, https://doi.org/10.1080/10428194.2020.1725503.